NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

Evogene said that it plans to offer 5 million shares of its common stock at a proposed maximum offering price of $17.16 per share. If the underwriters on the offering exercise their overallotment option, that figure would rise to $90 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.